composition, method to reduce blood glucose levels, weight gain or fat deposit levels, or treatment, adipocyte beige induction method or preventing pancreatic beta cell degeneration, and lyn kinase activator and agonist of trpm8 for use in reducing blood glucose levels, weight gain or fat deposit levels, or treatment.
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE;MELIOR PHARMACEUTICALS I, INC.
发明人:
ANDREW G. REAUME,ANN COULTER,FRANK GREENWAY,WEINA CONG
申请号：
BR112019021140
公开号：
BR112019021140A2
申请日:
2018.04.09
申请国别(地区):
BR
年份:
2020
代理人:
摘要：
the present disclosure provides compositions comprising a lyn kinase activator and trpm8 agonist and methods of: reducing blood glucose levels, weight gain or fat deposit levels； treatment of metabolic syndrome, syndrome x, obesity, pre-diabetes, type ii diabetes, type i diabetes； treatment of hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator-activated receptor-associated disorder, septicemia, a thrombotic disorder or pancreatitis； induction of adipocyte beige； and preventing pancreatic beta cell degeneration.a presente divulgação fornece composições que compreendem um ativador de lyn cinase e agonista de trpm8 e a métodos de: redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura； tratamento de síndrome metabólica, síndrome x, obesidade, pré-diabetes, diabetes tipo ii, diabetes tipo i； tratamento da hipercolesterolemia, hipertensão, doença cardíaca coronária, neuropatia diabética, lipodistrofia, retinopatia diabética, disfunção erétil, doença renal, dislipidemia, dislipoproteinemia, um distúrbio associado ao receptor ativado por proliferador de peroxissomo, septicemia, um distúrbio trombótico ou pancreatite； indução do bege de adipócitos； e prevenção da degeneração das células beta pancreáticas.
